Mike: Because the last stock I was in before AMBS
Post# of 30028
When it comes to MANF and everything else we have - I'm excited, but have no idea when they will cause our stock price to pop. MANF is still pre-clinical. I think the orphan designations will help us, but I really don't know how to quantify that. Starting an Eltoprazine phase 2b trial will help us, but I don't know how to quantify that, either. Same with Phenoguard. I'm very glad we have these therapeutic drugs in our pipeline, but I don't know when they will add significant shareholder value.